You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Organized Lipid Matrix: Fatty Acids and Choline in CF
SBC: AVANTI POLAR LIPIDS, INC. Topic: N/AIndividuals with cystic fibrosis (CF) and pancreatic insufficiency (PI) are prone to fat malabsorption, putting them at risk for caloric, essential fatty acid, and choline deficiency, which, in turn, may lead to growth failure and a poorer clinical course. Many subjects with CF have essential fatty acid deficiency, characterized by decreased levels of linoleic acid and an increased triene/tetraene ...
SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health -
A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce
SBC: Stratatech Corporation Topic: NIDDKDESCRIPTION (provided by applicant): The goal of this Type 2 Competitive Renewal SBIR application to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct a phase I/II clinical trial to investigate the safety and earlyefficacy of a novel antimicrobial living human skin substitute for the treatment of a life-threatening complication of diabetes: chronic, nonhea ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Commercial Readiness for Direct-to-Digital Pathology
SBC: APPLIKATE TECHNOLOGIES, INC. Topic: NCIAbstract Project Summary Applikate Technologies has developed Clearing Histology with Multiphoton Microscopy (CHiMP), a novel tissue processing and imaging platform that provides direct-to-digital images from intact pathology tissue specimens, such as biopsies, without the need for wax embedding, slicing, or scanning of slides. The application of this technology to cancer diagnosis will reduce err ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Antibody-Biocide Fusions to Control Cryptosporidium
SBC: IOGENETICS, LLC Topic: N/ADESCRIPTION (provided by applicant): The goal of this research is develop therapeutic products for Cryptosporidium parvum which can be made at a scale and cost which are feasible for delivery to large populations of patients or individuals at risk, as may be necessary in countering bioterrorism, or in protecting field-deployed armed forces. Our approach is to develop recombinant neutralizing mon ...
SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health -
Mitochondrial DNA repair agents for acute lung injury
SBC: EXSCIEN CORPORATION Topic: NHLBIDESCRIPTION provided by applicant Attempts to develop drug treatments for acute lung injury ALI and the acute respiratory distress syndrome ARDS have been marred by unfulfilled expectations Such failures often attributed to the heterogeneous pathophysiology of ALI ARDS and uncertainty about molecular targets of drug action have combined to fuel considerable skepticism about future dru ...
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Mobile Fetal Magentocardiography
SBC: Shared Medical Technology, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): Over 1.1 million conceptuses and fetuses die spontaneously each year, nearly 28,000 after 20 weeks' gestation. 12.5% of all infants are delivered prematurely, and the cost of care for the prematurely born is nearly 27 billion dollars annually. Prenatal assessment is currently dominated by ultrasound-based techniques; however, these are limited in their ability ...
SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antimicrobial Cellular Therapeutic for Inhibition of Biofilm Fo
SBC: Stratatech Corporation Topic: NIAIDDESCRIPTION (provided by applicant): Chronic and infected wounds significantly affect the quality of life for millions of US citizens and are associated with increased risk of complications including the devastating consequence of amputation. As of 2006, infections of diabetic foot ulcers resulted in 82,000 amputations each year and it has been estimated that these numbers will increase by 10% ann ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Delivery system development for a reservoir targeted Lyme disease vaccine
SBC: FoodSource Lure Corporation Topic: NIAIDDESCRIPTION (provided by applicant): The incidence and geographic distribution of Lyme disease in the U.S. has increased steadily since its first description in 1977. Efforts to stem the spread of the disease through controlling the population of its tickvector and/or the mouse reservoirs of the disease have met with only limited success. The only approved human vaccine to protect against Lyme di ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
GalT-KO Pigs Expressing Primate CD47 to Facilitate Organ Xenografts
SBC: MINITUBE OF AMERICA Topic: NIAIDDESCRIPTION (provided by applicant): Xenotransplantation with pig organs offers the best near term hope for satisfying the limitation imposed by shortage of human organs. This research project is directed toward producing as a product a genetically modified pig that will be the best potential donor for xenotransplants to humans. Although hyperacute rejection of pig organs in primate recipients ...
STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health -
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
SBC: SCARAB GENOMICS, LLC Topic: NIAIDScarab Genomics has established a unique, tiny footprint, extended bacterial fermentation process enabled by its reduced genome E. coli, for production of protein therapeutics, especially vaccine conjugates. The process will massively reduce the cost and upgrade the quality of these critical vaccine components. This Phase IIB resubmission focuses on commercial development of Scarab’s first vacci ...
SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health